BioMolecular Therapeutics Inks Deal with Samyang, Aims for Korean IND in '13 | GenomeWeb

By Doug Macron

With a second generation of its core asymmetric siRNA technology in the works, Korean drug developer BioMolecular Therapeutics announced last month that it has forged an RNAi research collaboration with Korea's Samyang.

Meanwhile, BMT is advancing its own programs in scar prevention and dry age-related macular degeneration, and aims to have its first investigational new drug application filed with Korean regulators sometime next year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.